30 Sep 2019 07:00
30 September 2019
AIM: AMYTEuronext Growth: AYP
Amryt Pharma plc
("Amryt" or the "Company")
INVESTOR EVENTS UPDATE
Amryt, a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases today provides an update on investor events that the Company will attend over the coming months in the UK and the US.
3-4 October 2019 Cantor Fitzgerald Global Healthcare Conference,
New York, NY.
10 October 2019 Shares Magazine Investor Evening,
Macdonald Hotel, London Rd, Manchester, M1 2PG
Time: 18.00
23 October 2019 Shares Magazine Investor Evening,
Novotel Tower Bridge, 10 Pepys St, London EC3N 2NR
Time: 18.00
24 October 2019 Proactive Investors One2One Investor Forum,
Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, London W1J 5EB Time: 18.00
19-20 November 2019 Stifel Healthcare Conference,
New York, NY.
20-21 November 2019 Jefferies Global Healthcare Conference,
London, UK.
21 November 2019 Proactive Investors One2One Investor Forum,
Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, London W1J 5EB Time: 18.00
27 November 2019 Shares Magazine Investor Evening,
Novotel Tower Bridge, 10 Pepys St, London EC3N 2NR
Time: 18.00
No new material information will be disclosed by management at the events.
Enquiries:
Amryt Pharma plc | +353 (1) 518 0200 |
Joe Wiley, CEO Rory Nealon, CFO/COO
|
|
Shore Capital |
+44 (0) 20 7408 4090 |
NOMAD and Joint Broker |
|
Edward Mansfield, Mark Percy, Daniel Bush, John More |
|
Stifel |
+44 (0) 20 7710 7600 |
Joint Broker |
|
Jonathan Senior, Ben Maddison
|
|
Davy | +353 (1) 679 6363 |
ESM Adviser and Joint Broker |
|
John Frain, Daragh O'Reilly
|
|
Consilium Strategic Communications | +44 (0) 20 3709 5700 |
Amber Fennell, Matthew Neal, David Daley
|
|
LifeSci Advisors, LLC | +1 (212) 915 2564 |
Tim McCarthy
|
|
About Amryt
Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a strong and growing portfolio of commercial and development assets.
Amryt's commercial business comprises two orphan disease products.
Juxtapid®/ Lojuxta® (lomitapide) is approved as an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the rare cholesterol disorder, Homozygous Familial Hypercholesterolaemia ("HoFH") in the US, Canada, Columbia, Argentina and Japan (under the trade name, Juxtapid®) and in the EU (under the trade name, Lojuxta®). HoFH is a rare genetic disorder which impairs the body's ability to remove low density lipoprotein ("LDL") cholesterol ("bad" cholesterol) from the blood, typically leading to abnormally high blood LDL cholesterol levels in the body from before birth - often ten times more than people without HoFH - and subsequent aggressive and premature cardiovascular disease.
Myalept® / Myalepta® (metreleptin) is approved in the US (under the trade name, Myalept®) as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy (GL) and in the EU (under the trade name, Myalepta®) for the treatment of leptin deficiency in patients with congenital or acquired GL in adults and children two years of age and above and familial or acquired partial lipodystrophy (PL) in adults and children 12 or over for whom standard treatments have failed to achieve adequate metabolic control. Metreleptin is also approved for lipodystrophy in Japan. Generalised and partial lipodystrophy are rare disorders characterised by loss or lack of adipose tissue resulting in the deficiency of the hormone leptin, produced by fat cells and are associated with severe metabolic abnormalities including severe insulin resistance, diabetes, hypertriglyceridemia and fatty liver disease.
Amryt's lead development candidate, AP101 (Oleogel-S10), is a potential treatment for the cutaneous manifestations of Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatment. It is currently being studied in a Phase 3 clinical trial and recently reported that unblinded interim efficacy data supported continuation of the study with a modest increase in sample size and unblinded interim safety data allowed the inclusion of children from as young as 21 days old. The European and US market opportunity for EB is estimated by the Directors to be in excess of $1 billion.
In March 2018, Amryt in-licenced a pre-clinical gene-therapy platform technology, AP103, which offers a potential treatment for patients with Recessive Dystrophic Epidermolysis Bullosa, a subset of EB, and is also potentially relevant to other genetic disorders.
For more information on Amryt, including products please visit www.amrytpharma.com